Status:

COMPLETED

Differences in Atorvastatin Metabolite Ratios as a Diagnostic Tool in Detecting Atorvastatin Induced Myotoxicity

Lead Sponsor:

Oslo University Hospital

Collaborating Sponsors:

University of Oslo School of Pharmacy

Conditions:

Muscular Diseases

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

The primary objective of the study is to investigate whether differences in atorvastatin metabolite ratios might have a positive or negative predictive value in diagnosing atorvastatin muscle toxicity...

Detailed Description

The primary objective of the study is to investigate whether differences in atorvastatin metabolites ratios might have a positive or negative predictive value in diagnosing atorvastatin muscle toxicit...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Suspected atorvastatin induced muscle adverse events
  • Signed informed consent
  • 18 years of age or older
  • Able to donate blood samples
  • Ongoing treatment with atorvastatin (not necessary if patients only donate a muscle biopsy)

Exclusion

    Key Trial Info

    Start Date :

    October 1 2005

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    December 1 2008

    Estimated Enrollment :

    53 Patients enrolled

    Trial Details

    Trial ID

    NCT00199745

    Start Date

    October 1 2005

    End Date

    December 1 2008

    Last Update

    May 10 2012

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Lipidklinikken, Rikshospitalet-Radiumhospitalet HF

    Oslo, Oslo County, Norway, 0027